Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin + radiotherapy followed by an adjuvant chemotherapy
Uterine Cervical Cancer
DRUG: Gemcitabine|PROCEDURE: Radiotherapy|DRUG: Cisplatin
Progression-free survival, 3 years after the end of study treament
Global survival, 5 years after the end of study treatment|safety, untill 5 years after study treatment
The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin + radiotherapy followed by an adjuvant chemotherapy